You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ABACAVIR SULFATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Abacavir Sulfate, and what generic alternatives are available?

Abacavir Sulfate is a drug marketed by Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Apotex Inc, Cipla, Mylan Pharms Inc, Strides Pharma, Norvium Bioscience, Aurobindo Pharma, Chartwell Rx, Laurus, Teva Pharms Usa, Zydus Pharms, and Lupin Ltd. and is included in seventeen NDAs.

The generic ingredient in ABACAVIR SULFATE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ABACAVIR SULFATE?
  • What are the global sales for ABACAVIR SULFATE?
  • What is Average Wholesale Price for ABACAVIR SULFATE?
Drug patent expirations by year for ABACAVIR SULFATE
Recent Clinical Trials for ABACAVIR SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cynthia L Gay, MDN/A
ViiV HealthcareN/A
University of North Carolina, Chapel HillN/A

See all ABACAVIR SULFATE clinical trials

Paragraph IV (Patent) Challenges for ABACAVIR SULFATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZIAGEN Oral Solution abacavir sulfate 20 mg/mL 020978 1 2012-12-27
ZIAGEN Tablets abacavir sulfate 300 mg 020977 1 2009-01-28

US Patents and Regulatory Information for ABACAVIR SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd ABACAVIR SULFATE abacavir sulfate SOLUTION;ORAL 077950-001 Mar 14, 2018 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan Pharms Inc ABACAVIR SULFATE abacavir sulfate TABLET;ORAL 091294-001 Jun 18, 2012 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Aurobindo Pharma Ltd ABACAVIR SULFATE abacavir sulfate TABLET;ORAL 077844-001 Dec 17, 2012 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Chartwell Rx ABACAVIR SULFATE AND LAMIVUDINE abacavir sulfate; lamivudine TABLET;ORAL 204990-001 Mar 28, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Strides Pharma ABACAVIR SULFATE abacavir sulfate TABLET;ORAL 091050-001 Oct 28, 2016 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Zydus Pharms ABACAVIR SULFATE AND LAMIVUDINE abacavir sulfate; lamivudine TABLET;ORAL 208990-001 Nov 15, 2018 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ABACAVIR SULFATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Abacavir Sulfate

Introduction

Abacavir sulfate, an antiretroviral drug used to treat HIV-1 infection, is a crucial component in the global pharmaceutical market. This article delves into the market dynamics and financial trajectory of abacavir sulfate, highlighting key trends, drivers, and challenges.

Market Size and Growth Projections

The abacavir sulfate market, including both the reagent and API segments, is poised for significant growth. Reports indicate that the market has experienced rapid and substantial growth in recent years and is expected to continue this upward trend from 2023 to 2031[1][4].

Abacavir Sulfate Reagent Market

The reagent market is segmented based on type (min purity less than 98%, min purity 98%-99%, min purity more than 99%) and application (research, medical) across various geographical regions. The positive trend in market dynamics suggests robust growth rates, driven by increasing demand in research and medical applications[1].

Abacavir Sulfate API Market

The API market, similarly segmented by type and application (research, pharmaceutical), also forecasts continued expansion. This growth is attributed to the increasing need for high-purity APIs in pharmaceutical manufacturing and research[4].

Drivers of Market Growth

Several factors drive the growth of the abacavir sulfate market:

Increasing Demand for HIV Treatment

The global need for effective HIV treatments continues to rise, driving demand for antiretroviral drugs like abacavir sulfate. Innovations in treatment regimens and the introduction of new combination therapies further boost market growth[3].

Advancements in Research and Development

Continuous research and development in the pharmaceutical sector, particularly in antiretroviral therapies, contribute to the market's expansion. Clinical trials and studies on the pharmacokinetics and safety of abacavir sulfate in various patient populations support its widespread adoption[3].

Regulatory Support

Regulatory bodies' approval and support for new treatments and formulations of abacavir sulfate facilitate market growth. For instance, the FDA's approval of new combination therapies and generic versions of the drug helps in increasing its accessibility and affordability[3].

Restraints and Challenges

Despite the positive outlook, several challenges affect the market:

Patent Expiries and Generic Competition

The loss of patent exclusivity for branded drugs can lead to significant reductions in spending due to generic competition. For example, the patent expiry of similar drugs has resulted in substantial reductions in spending, a trend that could impact abacavir sulfate if generic versions become widely available[2].

Pricing and Rebates

The pharmaceutical market is heavily influenced by pricing strategies and rebates. High invoice price increases can be offset by off-invoice discounts and rebates, affecting the net price growth of the drug. This dynamic can impact the revenue projections for abacavir sulfate[2].

Regulatory and Compliance Issues

Changing regulatory landscapes, such as new sustainability reporting requirements and ESG disclosures, can pose challenges for pharmaceutical companies. Compliance with these regulations can be costly and time-consuming, potentially affecting market dynamics[5].

Market Segmentation

The abacavir sulfate market is segmented into several key categories:

By Type

  • Min Purity Less Than 98%
  • Min Purity 98%-99%
  • Min Purity More Than 99%

These segments cater to different needs in research and pharmaceutical applications, with higher purity levels typically commanding higher prices[1][4].

By Application

  • Research
  • Medical (Pharmaceutical)

The research segment drives demand for reagents, while the pharmaceutical segment is crucial for API sales[1][4].

By Geographical Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle-East and Africa

Each region has its own market dynamics, influenced by local healthcare policies, economic conditions, and regulatory environments[1][4].

Financial Trajectory

The financial outlook for the abacavir sulfate market is optimistic, with projections indicating significant revenue growth:

Revenue Projections

The market size of both the reagent and API segments is expected to increase substantially from 2023 to 2031, measured in USD million. This growth is driven by increasing demand, new product launches, and expanding geographical reach[1][4].

Key Financial Metrics

  • Market Size: Expected to grow significantly over the forecast period.
  • Growth Rate: Robust growth rates anticipated due to favorable market dynamics.
  • Revenue: Projected to increase across all segments, driven by research, medical, and geographical expansion[1][4].

Industry Expert Insights

Industry experts highlight the importance of continuous innovation and regulatory compliance in driving market growth.

"The pharmaceutical industry is highly regulated, and compliance with evolving ESG and regulatory requirements is crucial for sustained growth. Companies must balance innovation with ethical and responsible practices to maintain market leadership," - [GSK ESG Performance Report 2023][5].

Illustrative Statistics

  • The abacavir sulfate reagent market is expected to experience robust growth rates, with the market size projected to increase significantly from 2023 to 2031[1].
  • In 2014, spending on new brand medicines, including those for HIV, increased dramatically, totaling $12.3 billion for hepatitis C treatments alone[2].
  • Clinical trials have shown that abacavir sulfate, when combined with other antiretroviral drugs, demonstrates favorable pharmacokinetic parameters and safety profiles[3].

Key Takeaways

  • The abacavir sulfate market is poised for significant growth driven by increasing demand for HIV treatments and advancements in research and development.
  • Market segmentation by type, application, and geographical region highlights diverse growth opportunities.
  • Regulatory support and compliance are critical for market expansion.
  • Challenges such as patent expiries, pricing dynamics, and regulatory changes must be navigated to sustain growth.

FAQs

What is the primary use of abacavir sulfate?

Abacavir sulfate is primarily used to treat HIV-1 infection in conjunction with other antiretroviral drugs.

What are the key segments of the abacavir sulfate market?

The market is segmented by type (min purity levels), application (research, medical), and geographical regions.

How is the market expected to grow from 2023 to 2031?

The market is expected to experience robust growth rates, driven by increasing demand and favorable market dynamics.

What are the main challenges facing the abacavir sulfate market?

Challenges include patent expiries, generic competition, pricing and rebate dynamics, and regulatory compliance issues.

How does regulatory support impact the abacavir sulfate market?

Regulatory support, such as FDA approvals and compliance with ESG regulations, facilitates market growth by ensuring the drug's safety, efficacy, and accessibility.

Sources

  1. Market Research Intellect, "Abacavir Sulfate Reagent Market Size, Scope And Forecast Report"
  2. Vermont Legislature, "Medicines Use and Spending Shifts"
  3. NCBI Bookshelf, "Abacavir - StatPearls"
  4. Market Research Intellect, "Abacavir Sulfate API Market Size, Scope And Forecast Report"
  5. GSK, "ESG Performance Report 2023"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.